ERBB2 and breast cancer: Data from MINDACT, TAILORx, and RxPonder phase III trials—genomically driven adjuvant BC clinical studies—suggest that most of the benefit of adjuvant chemotherapy in reducing HR+/HER2 negative BC mortality in patients with genomically low risk tumors is confined to women under age 50 (and therefore more likely pre‐menopausal).7, 15, 16, 17